Contact
Please use this form to send email to PR contact of this press release:
Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
TO:
Please use this form to send email to PR contact of this press release:
Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
TO: